SPRINGFIELD, Mass. (WWLP) – Pfizer’s RSV vaccine also known as Abrysvo is showing the potential to protect adults ages 18 to 59 who are at high risk of getting sick. Officials investigate rare ...

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.

Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower respiratory tract disease ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the ...

GSK's vaccine Arexvy and Pfizer's shot Abrysvo are approved for use in individuals over the age of 60 in the UK. (Reporting ...

In the first domestic ITF Masters event of 2025 on Canadian soil, the hosts dominated by claiming every trophy at the ...

In a earnings report Tuesday, Pfizer said sales of its vaccine Abrysvo fell 62% year over year in the fourth quarter. The company attributed the drop mainly to “a significant reduction in ...

The man behind the so-called "DOGE Dividend," investor James Fishback, joins NewsNation's "CUOMO" to discuss Trump's promise that taxpaying Americans could receive a $5,000 check — thanks to DOGE.